Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis
Our previous study found copy number variation of chromosome fragment 5p13.1-13.3 might involve in the progression of ovarian cancer. In the current study, the alteration was validated and complement component 7 (C7), located on 5p13.1, was identified. To further explore the clinical value of C7 in tumors, 156 malignant, 22 borderline, 33 benign and 24 normal ovarian tissues, as well as 173 non-small cell lung cancer (NSCLC) tissues along with corresponding adjacent and normal tissues from the tissue bank of Zhejiang Cancer Hospital were collected. The expression of C7 was analyzed using reverse transcriptase quantitative polymerase chain reaction. As a result, the C7 expression displayed a gradual downward trend in normal, benign, borderline and malignant ovarian tissues, and the decreased expression of C7 was correlative to poor differentiation in patients with ovarian cancer. Interestingly, a similar change of expression of C7 was found in normal, adjacent and malignant tissues in patients with NSCLC, and low expression of C7 was associated with worse grade and advanced clinical stage. Both results from this cohort and the public database indicated that NSCLC patients with low expression of C7 had a worse outcome. Furthermore, multivariate cox regression analysis showed NSCLC patients with low C7 had a 3.09 or 5.65-fold higher risk for relapse or death than those with high C7 respectively, suggesting C7 was an independent prognostic predictor for prognoses of patients with NSCLC. Additionally, overexpression of C7 inhibited colony formation of NSCLC cells, which hints C7 might be a potential tumor suppressor.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Oncotarget - 7(2016), 52 vom: 27. Dez., Seite 86536-86546 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ying, Lisha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Complement C7 |
|---|
| Anmerkungen: |
Date Completed 22.02.2018 Date Revised 20.09.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18632/oncotarget.13294 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM266242685 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM266242685 | ||
| 003 | DE-627 | ||
| 005 | 20231224214051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.13294 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0887.xml |
| 035 | |a (DE-627)NLM266242685 | ||
| 035 | |a (NLM)27852032 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ying, Lisha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2018 | ||
| 500 | |a Date Revised 20.09.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Our previous study found copy number variation of chromosome fragment 5p13.1-13.3 might involve in the progression of ovarian cancer. In the current study, the alteration was validated and complement component 7 (C7), located on 5p13.1, was identified. To further explore the clinical value of C7 in tumors, 156 malignant, 22 borderline, 33 benign and 24 normal ovarian tissues, as well as 173 non-small cell lung cancer (NSCLC) tissues along with corresponding adjacent and normal tissues from the tissue bank of Zhejiang Cancer Hospital were collected. The expression of C7 was analyzed using reverse transcriptase quantitative polymerase chain reaction. As a result, the C7 expression displayed a gradual downward trend in normal, benign, borderline and malignant ovarian tissues, and the decreased expression of C7 was correlative to poor differentiation in patients with ovarian cancer. Interestingly, a similar change of expression of C7 was found in normal, adjacent and malignant tissues in patients with NSCLC, and low expression of C7 was associated with worse grade and advanced clinical stage. Both results from this cohort and the public database indicated that NSCLC patients with low expression of C7 had a worse outcome. Furthermore, multivariate cox regression analysis showed NSCLC patients with low C7 had a 3.09 or 5.65-fold higher risk for relapse or death than those with high C7 respectively, suggesting C7 was an independent prognostic predictor for prognoses of patients with NSCLC. Additionally, overexpression of C7 inhibited colony formation of NSCLC cells, which hints C7 might be a potential tumor suppressor | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a complement component 7 | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a tumor progression | |
| 650 | 7 | |a Complement C7 |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Proteins |2 NLM | |
| 700 | 1 | |a Zhang, Fanrong |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Xiaodan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Kaiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Jiaoyue |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Junzhou |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Jianguo |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Herbert |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Hongchuan |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Dan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 7(2016), 52 vom: 27. Dez., Seite 86536-86546 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2016 |g number:52 |g day:27 |g month:12 |g pages:86536-86546 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.13294 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2016 |e 52 |b 27 |c 12 |h 86536-86546 | ||